Anika Therapeutics | ANIK - Net Income


Anika Therapeutics reported $292K in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Abbott USD 1.78B 132M Dec/2025
Agenus USD -10.63M 74.49M Dec/2025
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -328.48M 41.54M Dec/2025
Integra LifeSciences USD -1.7M 3.7M Dec/2025
J&J USD 5.12B 36M Dec/2025
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Ligand Pharmaceuticals USD 117.27M 112.43M Sep/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Merit Medical Systems USD 27.76M 4.83M Sep/2025
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR -801M 3.6B Dec/2025
Smith & Nephew USD 293M 79M Dec/2025
Stryker USD 849M 10M Dec/2025
Surmodics USD -5.32M 6.22M Jun/2025
Veracyte USD 41.15M 22.01M Dec/2025
Xencor USD -6.65M 626K Dec/2025
Zimmer Biomet Holdings USD 139.3M 91.6M Dec/2025